# Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum

> **NCT05355467** · PHASE4 · COMPLETED · sponsor: **Mylan (Taiwan) Ltd** · enrollment: 40 (actual)

## Conditions studied

- Chronic Hepatitis B Infection

## Interventions

- **DRUG:** Tenofovir disoproxil fumarate
- **OTHER:** Historical Data

## Key facts

- **NCT ID:** NCT05355467
- **Lead sponsor:** Mylan (Taiwan) Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-21
- **Primary completion:** 2021-07-13
- **Final completion:** 2021-07-13
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05355467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05355467, "Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05355467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*